RESUMO
OBJECTIVE: Lidocaine 5% patches are approved for the treatment of post-herpetic neuralgia in adults. Little information is available on the penetration of lidocaine into skin and skin-related soft tissue, which are thought to be closer to the site where lidocaine exerts its pharmacological action on neuronal structures. This pilot study investigated subcutaneous and systemic pharmacokinetics of lidocaine during topical application of two different lidocaine 5% patches. MATERIALS AND METHODS: This randomized two-way, two-period crossover study assessed lidocaine concentrations in subcutaneous tissue (by microdialysis) and plasma of n = 5 healthy subjects during 12-hour-long applications of a recently developed lidocaine 5% patch (Laboratorios Gebro Pharma, SA, Barcelona, Spain) and a marketed reference patch (Versatis 5% lidocaine patch, Grünenthal, Brunn am Gebirge, Austria), respectively. RESULTS: Lidocaine was detectable in subcutaneous tissue within 60 minutes from start of patch application, and in plasma only after a marked delay. The test formulation led to increased exposure to lidocaine in both subcutaneous tissue and plasma. CONCLUSION: This study has underscored the potential of microdialysis to comparatively assess the pharmacokinetics of two different drug formulations and encourages its further use in this area.
Assuntos
Anestésicos Locais , Lidocaína , Administração Cutânea , Adulto , Anestésicos Locais/uso terapêutico , Estudos Cross-Over , Humanos , Microdiálise , Projetos PilotoRESUMO
Fabry disease (FD, OMIM 301500) is a rare X-linked inherited lysosomal storage disorder associated with reduced activities of α-galactosidase A (aGal, EC 3.2.1.22). The current standard of care for FD is based on enzyme replacement therapy (ERT), in which a recombinantly produced version of αGal is intravenously (iv) applied to Fabry patients in biweekly intervals. Though the iv application is clinically efficacious, periodical infusions are inconvenient, time- and resource-consuming and they negatively impact the patients' quality of life. Subcutaneous (sc) injection, in contrast, is an established route of administration for treatment of chronic conditions. It opens the beneficial option of self-administration, thereby improving patients' quality of life and at the same time reducing treatment costs. We have previously shown that Moss-α-Galactosidase (moss-aGal), recombinantly produced in the moss Physcomitrium patens, is efficient in degrading accumulated Gb3 in target organs of murine model of FD and in the phase I clinical study, we obtained first efficacy evidence in human patients following single iv infusion. Here, we tested the efficacy of subcutaneous administration of moss-aGal and compared it with the results observed following iv infusion in Fabry mice. The obtained findings demonstrate that subcutaneously applied moss-aGal is correctly transported to target organs and efficacious in degrading Gb3 deposits there and thus suggest the possibility of using this route of administration for therapy of Fabry disease.
RESUMO
BACKGROUND: Hyperlipidemia and obesity are associated with metabolic syndrome and increased risk in developing diabetes and cardiovascular disease. Nutritional supplements, e.g. L-carnitine and polyunsaturated fatty acids (PUFAs), exert lipid-lowering effects. Hence, the hypothesis that dietetic intervention reduces plasma lipid levels and metabolic enzymes in overweight hyperlipidemic subjects was tested. SUBJECTS AND METHODS: In a prospective placebo-controlled double-blind study in 22 moderately hyperlipidemic obese humans consuming low-fat yoghurt enriched with a combination of low-dose PUFAs, polyphenols and L-carnitine (PPC) twice a day for 12 weeks were compared to 20 matching participants ingesting low-fat yoghurt. The effects on plasma lipids and expression of enzymes involved in regulation of fatty acid oxidation in peripheral blood mononuclear cells (PBMCs) and HepG2 cells were evaluated. RESULTS: PPC consumption led to significantly reduced plasma free fatty acid (-29%) and triglyceride (-24%) concentrations (each p < 0.05). PPC application increased significantly peroxisome proliferator-activated receptor α (PPARα) mRNA abundances and those of PPARα target genes (carnitine palmitoyltransferases-1, CPT1A and CPT1B, carnitine acetyltransferase and organic cation transporter 2; each p < 0.05) in PBMCs. In controls, plasma lipid levels and PBMC gene expression did not change. These findings were substantiated by the results of cell culture experiments in HepG2 cells. CONCLUSION: Supplementation of PPC had marked lipid-lowering effects and PBMC gene expression profiles seemed to reflect nutrition-related metabolic changes.
Assuntos
Carnitina/uso terapêutico , Ácidos Graxos Ômega-3/uso terapêutico , Ácidos Graxos/metabolismo , Flavonoides/uso terapêutico , Leucócitos Mononucleares/metabolismo , Lipídeos/sangue , Fenóis/uso terapêutico , Regulação para Cima , Adulto , Carnitina/administração & dosagem , Carnitina/metabolismo , Método Duplo-Cego , Ácidos Graxos Ômega-3/administração & dosagem , Ácidos Graxos Ômega-3/metabolismo , Feminino , Flavonoides/administração & dosagem , Flavonoides/metabolismo , Alimento Funcional/análise , Células Hep G2 , Hepatócitos/metabolismo , Humanos , Hiperlipidemias/sangue , Hiperlipidemias/dietoterapia , Hiperlipidemias/metabolismo , Hipolipemiantes/administração & dosagem , Hipolipemiantes/metabolismo , Masculino , Pessoa de Meia-Idade , Sobrepeso/complicações , Oxirredução , PPAR alfa/genética , PPAR alfa/metabolismo , Fenóis/administração & dosagem , Fenóis/metabolismo , Polifenóis , RNA Mensageiro/metabolismoRESUMO
Duramycin (Moli1901) is being developed for the treatment of reduced mucociliary clearance in cystic fibrosis. This study was conducted to estimate lung residence time and systemic exposure and to assess whether duramycin causes an inflammatory response. Six volunteers were administered a single dose (7.5 mg) of nebulized duramycin and underwent bronchoscopies to obtain a composite data set for pharmacokinetic analysis; duramycin was measured in the cellular fraction of bronchoalveolar lavage fluid (BALF) (mainly alveolar macrophages) and brush biopsies (bronchial epithelial cells). The estimated t(1/2) of duramycin was approximately 5 days in brush biopsies and 25 to 91 days in BALF cells. Levels of duramycin in BALF (C (max) 800 ng/mg) exceeded those in brush biopsies by approximately 20-fold. Duramycin was absent from plasma and did not cause any detectable inflammatory response in pulmonary tissue as judged from the BALF profile of 14 relevant cytokines. Our data suggest that duramycin qualifies for intrapulmonary administration in cystic fibrosis (CF) patients.
Assuntos
Antibacterianos/efeitos adversos , Antibacterianos/farmacocinética , Bacteriocinas/efeitos adversos , Bacteriocinas/farmacocinética , Pulmão/metabolismo , Peptídeos/efeitos adversos , Peptídeos/farmacocinética , Administração por Inalação , Adulto , Antibacterianos/administração & dosagem , Bacteriocinas/administração & dosagem , Líquido da Lavagem Broncoalveolar/química , Broncoscopia , Quimiocinas/análise , Quimiocinas/metabolismo , Cromatografia Líquida de Alta Pressão , Citocinas/análise , Citocinas/metabolismo , Meia-Vida , Humanos , Linfócitos/efeitos dos fármacos , Linfócitos/metabolismo , Masculino , Nebulizadores e Vaporizadores , Peptídeos/administração & dosagem , Espectrometria de Massas por Ionização por ElectrosprayRESUMO
A new and very sensitive analytical method has been developed and validated to jointly determine the anti-inflammatory drug ciclesonide (CIC), its active principle metabolite M1 (CIC-M1) and fluticasone propionate (FP) in human serum, in the low concentration range from 10 to 1000 pg/mL. This was accomplished by high-performance liquid chromatography and tandem mass spectrometry using atmospheric pressure photo ionisation (HPLC-MS/MS with APPI) using 0.5 mL of serum. Serum was mixed with the internal standards (IS) D11-CIC and D11-CIC-M1 and extracted with diisopropylether. A gradient with acetonitrile (containing 10 mM of acetic acid and 10% of acetone) was used. HPLC-MS/MS of the acetic acid adducts of the analytes was performed in negative mode. The novel aspect of this method is that instead of the dopant being introduced directly into the source by means of an external HPLC pump, it was added to the mobile phase. This provided significantly better sensitivity than the usual method of in-source addition of the dopant, and with no loss in HPLC performance. Sensitivity for the analytes was about four times greater than with either APCI or ESI. Validation was performed in three batches. The inter-batch precision (CV) of the quality control samples in human serum ranged from 4.08% to 6.78% for CIC, from 2.57% to 7.74% for CIC-M1, and from 2.38% to 9.61% for FP. The inter-batch accuracy (with reference to the mean value) of the quality control samples in human serum ranged from 99.3% to 110.0% for CIC, from 101.8% to 104.7% for CIC-M1, and from 100.4% to 101.8% for FP. Calibration data and LLOQ data are also presented in this paper. The analytes were stable in human serum over three freeze/thaw cycles, or for 4h at room temperature, or for at least 18 months when stored at below -20 degrees C. This method was used for quantifying the analytes after inhalation of low-mug amounts of the drugs by patients.
Assuntos
Androstadienos/sangue , Anti-Inflamatórios/sangue , Cromatografia Líquida de Alta Pressão/métodos , Pregnenodionas/sangue , Espectrometria de Massas em Tandem/métodos , Androstadienos/química , Androstadienos/isolamento & purificação , Anti-Inflamatórios/química , Anti-Inflamatórios/isolamento & purificação , Pressão Atmosférica , Fluticasona , Humanos , Pregnenodionas/química , Pregnenodionas/isolamento & purificação , Reprodutibilidade dos TestesRESUMO
An HPLC-MS/MS method was developed and validated for the determination of dihydralazine in human plasma. HPLC-MS/MS has not been used before in a published paper and provides better sensitivity and selectivity. Therefore a much easier sample preparation than published before is feasible (protein precipitation). As this substance is rather reactive and sensitive some specific care has to be taken hindering the conversion of the substance in whole blood and following human plasma after blood withdrawal. Hydrazines often are used for derivatization of aldehydes and ketones. With specific care (using 1,4-dithiothreitol (DTT) and cooling) dihydralazine can be preserved and analysed without decomposition or conversion in the tested range of 0.500-302 ng/mL of human plasma. The following inter-batch precision and accuracy of the Quality Control Samples resulted: QC-A (1.34 ng/mL plasma) with a precision of coefficient of variation (CV) 7.66% and an accuracy of 103.2%; QC-B (18.2 ng/mL 7.86%, acc. 101.3%); QC-C (258 ng/mL, 9.73%, acc. 98.3%). The inter-batch values of the LLOQ samples at 0.500 ng/mL were 7.17% for CV and accuracy of 106.4%. Mean recovery tested at the QC levels was found to be 103.8%. Specificity in six different plasma samples was good (<10% of the area of the LLOQ). Stability in plasma was tested under different conditions and was sufficient.
Assuntos
Anti-Hipertensivos/sangue , Cromatografia Líquida de Alta Pressão/métodos , Di-Hidralazina/sangue , Espectrometria de Massas em Tandem/métodos , Anti-Hipertensivos/química , Anti-Hipertensivos/farmacocinética , Disponibilidade Biológica , Cromatografia Líquida de Alta Pressão/normas , Estudos Cross-Over , Di-Hidralazina/química , Di-Hidralazina/farmacocinética , Ditiotreitol/química , Estabilidade de Medicamentos , Humanos , Modelos Lineares , Controle de Qualidade , Substâncias Redutoras/química , Valores de Referência , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Espectrometria de Massas em Tandem/normas , Temperatura , Fatores de TempoRESUMO
The method for the simultaneous determination of neomycin and bacitracin in human or rabbit serum was developed by using ion pairing reversed phase chromatography and tandem mass spectrometry (MS/MS) detection with electrospray (ESI) in positive mode. Both substances elute under these conditions at the same time and also kanamycin as internal standard elutes almost at the same time. The sample preparation was simple-only using 0.1 mL serum by protein precipitation with acetonitrile. Neomycin and bacitracin were detected as two-fold charged ions as well as the internal standard. The calibration range of these quite difficult detectable substances was 0.2-50 microg/mL of serum. The method was validated for both human or rabbit serum. The inter batch precision of quality control samples in human serum for neomycin ranged from 4.46% to 8.99% and for bacitracin from 6.85% to 11.17%. The inter batch accuracy for neomycin ranged from 98.7% to 100.7% and for bacitracin from 99.2% to 103.0%. At lower limit of quantitation (LLOQ) level of 0.2 microg/mL inter batch precision in human serum for neomycin was 12.05% and for bacitracin 11.91%, whereas accuracies were 99.9% for neomycin and 102.7% for bacitracin. Bench top stability in human or rabbit serum was given over three freeze thaw cycles and 4h at room temperature. The method can be considered to be specific and recoveries for sample preparation were high.
Assuntos
Antibacterianos/sangue , Bacitracina/sangue , Cromatografia Líquida de Alta Pressão/métodos , Neomicina/sangue , Espectrometria de Massas por Ionização por Electrospray/métodos , Espectrometria de Massas em Tandem/métodos , Animais , Antibacterianos/química , Bacitracina/química , Calibragem , Cromatografia Líquida de Alta Pressão/normas , Estabilidade de Medicamentos , Congelamento , Humanos , Canamicina/sangue , Modelos Lineares , Estrutura Molecular , Neomicina/química , Preparações Farmacêuticas/normas , Controle de Qualidade , Coelhos , Padrões de Referência , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Espectrometria de Massas por Ionização por Electrospray/normas , Espectrometria de Massas em Tandem/normasRESUMO
An analytical method was developed and validated to determine Formoterol in human serum in the range from 0.40 to 100.24 pg/mL by high performance liquid chromatography and tandem mass spectrometry (HPLC-MS/MS) due to the lack of efficient methods to determine very low levels of Formoterol in serum and plasma. Serum was diluted by water and mixed with the internal standard (d6-Formoterol). Formoterol and internal standard were extracted using a cation-exchange solid phase column (SCX-3). After eliminating endogenous serum constituents through washing steps with water and methanol, elution took place using methanol/ammonia. After evaporation of the elution liquid the residue was redissolved and analyzed by HPLC-MS/MS with electrospray ionisation (ESI) in positive mode. A gradient between 10 mM ammonium formate and acetonitrile was used. The inter-batch precision of the calibration standards ranged from 1.55% to 9.01%. The inter-batch accuracy of the calibration standards ranged from 93.37% to 107.30%. The lower limit of quantitation (LLOQ, 0.40 pg/mL) had a precision of 19.67% and an accuracy of 96.78%. Comparable results were obtained for quality control samples. Stability in human serum was given over three freeze/thaw cycles and 2h at room temperature. Formoterol in human serum was stable for at least 6 months below -20 degrees C. This method has been used widely for quantifying Formoterol after inhalation of 9-36 microg of the drug by volunteers. A cross validation with human plasma versus serum was performed after this method was successfully validated in human serum.
Assuntos
Agonistas Adrenérgicos beta/sangue , Cromatografia Líquida de Alta Pressão/métodos , Etanolaminas/sangue , Espectrometria de Massas por Ionização por Electrospray/métodos , Agonistas Adrenérgicos beta/farmacocinética , Etanolaminas/farmacocinética , Fumarato de Formoterol , Humanos , Controle de Qualidade , Padrões de Referência , Reprodutibilidade dos Testes , Sensibilidade e EspecificidadeRESUMO
Obesity-induced chronic low-grade inflammation originates from adipose tissue and is crucial for obesity-driven metabolic deterioration, including insulin resistance and type 2 diabetes. Chronic inflammation may be a consequence of a failure to actively resolve inflammation and could result from a lack of local specialized proresolving lipid mediators (SPMs), such as resolvins and protectins, which derive from the n-3 polyunsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). We assessed obesity-induced changes of n-3-derived SPMs in adipose tissue and the effects of dietary EPA/DHA thereon. Moreover, we treated obese mice with SPM precursors and investigated the effects on inflammation and metabolic dysregulation. Obesity significantly decreased DHA-derived 17-hydroxydocosahexaenoic acid (17-HDHA, resolvin D1 precursor) and protectin D1 (PD1) levels in murine adipose tissue. Dietary EPA/DHA treatment restored endogenous biosynthesis of n-3-derived lipid mediators in obesity while attenuating adipose tissue inflammation and improving insulin sensitivity. Notably, 17-HDHA treatment reduced adipose tissue expression of inflammatory cytokines, increased adiponectin expression, and improved glucose tolerance parallel to insulin sensitivity in obese mice. These findings indicate that impaired biosynthesis of certain SPM and SPM precursors, including 17-HDHA and PD1, contributes to adipose tissue inflammation in obesity and suggest 17-HDHA as a novel treatment option for obesity-associated complications.
Assuntos
Ácidos Docosa-Hexaenoicos/uso terapêutico , Inflamação/tratamento farmacológico , Inflamação/imunologia , Obesidade/tratamento farmacológico , Obesidade/imunologia , Tecido Adiposo/metabolismo , Animais , Western Blotting , Ácidos Docosa-Hexaenoicos/metabolismo , Ácido Eicosapentaenoico/uso terapêutico , Citometria de Fluxo , Humanos , Imuno-Histoquímica , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Obesidade/metabolismo , Reação em Cadeia da Polimerase Via Transcriptase ReversaRESUMO
Recently, lyso-globotriaosylsphingosine (lyso-Gb3) was found to be elevated in plasma of treatment naive male patients and some female patients with Fabry Disease (FD). This study tested whether lyso-Gb3 could be analyzed in dried blood spots (DBS) from filter cards and whether concentrations are elevated in newborn infants with FD. Lyso-Gb3 concentrations were analyzed in DBS following extraction using a novel HPLC-mass spectrometry (MS)/MS method. Lyso-Gb3 levels in DBS were above the lower limit of quantitation (0.28 ng/mL) in 5/17 newborn FD infants (16 males; range: 1.02-8.81 ng/mL), but in none of the newborn controls, in all 13 patients (4 males) with classic FD (range: 2.06-54.1 ng/mL), in 125/159 Taiwanese individuals with symptomatic or asymptomatic FD who carry the late onset α-galactosidase A (GLA) mutation c.936+919G>A (IVS4+919G>A) (3.75±0.69 ng/mL; range: 0.418-3.97 ng/mL) and in 20/29 healthy controls (0.77±0.24 ng/mL; range: 0.507-1.4 ng/mL). The HPLC-MS/MS method for analysis of lyso-Gb3 is robust and yields reproducible results in DBS in patients with FD. However, concentrations of lyso-Gb3 were below the limit of quantitation in most newborn infants with FD rendering this approach not suitable for newborn screening. In addition, most females with the late onset mutation have undetectable lyso-Gb3 concentrations.
Assuntos
Análise Química do Sangue/métodos , Teste em Amostras de Sangue Seco , Glicolipídeos/sangue , Esfingolipídeos/sangue , Adolescente , Adulto , Criança , Cromatografia Líquida de Alta Pressão , Doença de Fabry/sangue , Doença de Fabry/diagnóstico , Feminino , Humanos , Recém-Nascido , Masculino , Espectrometria de Massas em Tandem , Adulto JovemRESUMO
BACKGROUND: Gaucher disease (GD) is the most common lysosomal storage disorder (LSD). Based on a deficient ß-glucocerebrosidase it leads to an accumulation of glucosylceramide. Standard diagnostic procedures include measurement of enzyme activity, genetic testing as well as analysis of chitotriosidase and CCL18/PARC as biomarkers. Even though chitotriosidase is the most well-established biomarker in GD, it is not specific for GD. Furthermore, it may be false negative in a significant percentage of GD patients due to mutation. Additionally, chitotriosidase reflects the changes in the course of the disease belatedly. This further enhances the need for a reliable biomarker, especially for the monitoring of the disease and the impact of potential treatments. METHODOLOGY: Here, we evaluated the sensitivity and specificity of the previously reported biomarker Glucosylsphingosine with regard to different control groups (healthy control vs. GD carriers vs. other LSDs). FINDINGS: Only GD patients displayed elevated levels of Glucosylsphingosine higher than 12 ng/ml whereas the comparison controls groups revealed concentrations below the pathological cut-off, verifying the specificity of Glucosylsphingosine as a biomarker for GD. In addition, we evaluated the biomarker before and during enzyme replacement therapy (ERT) in 19 patients, demonstrating a decrease in Glucosylsphingosine over time with the most pronounced reduction within the first 6 months of ERT. Furthermore, our data reveals a correlation between the medical consequence of specific mutations and Glucosylsphingosine. INTERPRETATION: In summary, Glucosylsphingosine is a very promising, reliable and specific biomarker for GD.
Assuntos
Biomarcadores/metabolismo , Doença de Gaucher/diagnóstico , Doença de Gaucher/metabolismo , Psicosina/análogos & derivados , Adolescente , Adulto , Biomarcadores/análise , Criança , Pré-Escolar , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Psicosina/análise , Psicosina/metabolismo , População Branca , Adulto JovemRESUMO
The AP301 peptide mimics the lectin-like domain of TNF-α. The synthetic peptide AP301 (molecular weight 1923.1amu) is composed of 17 amino acids and contains an intramolecular disulfide bond between the N-terminal and the C-terminal cysteine. AP301 interacts with the endothelial sodium channel (ENaC) and activates pulmonary liquid clearance both in vitro and in animal studies. Currently, AP301 is subject to clinical investigations for the treatment of pulmonary oedema. With HPLC-MS/MS on reversed phase chromatography a determination limit of 1ng AP301/mL human plasma can be achieved. The MS-ionisation was done with ESI positive. 50µL of human plasma was mixed with the internal standard (a stable isotope labelled AP301, with a total of 6 carbon 13) in acetonitrile for protein precipitation. After centrifugation a part of the clear supernatant was injected into HPLC-MS/MS. Validation was performed according to FDA-guideline in three batches [U.S. Department of Health and Human Services, Food and Drug Administration (FDA): Guidance for Industry, Bioanalytical Method Validation, May 2001]. By using a 6xC13 isotopically labelled internal standard good precision, accuracy and linearity can be gained. The inter-batch precision (CV) of the quality control samples in human plasma (conc. 2.50/20/240ng/mL) ranged from 5.54 to 10.15%. The inter-batch accuracy (with reference to the mean value) of the quality control samples in plasma ranged from 96.1% to 99.9%. The analyte was stable in human plasma over three freeze/thaw cycles, or for 4h at room temperature, or for at least 20weeks when stored at below -20°C. This method was used for quantifying AP301 after inhalative application in a phase I-study.
Assuntos
Cromatografia Líquida de Alta Pressão/métodos , Peptídeos/sangue , Espectrometria de Massas em Tandem/métodos , Fator de Necrose Tumoral alfa/química , Motivos de Aminoácidos , Sequência de Aminoácidos , Ensaios Clínicos Fase I como Assunto/métodos , Estabilidade de Medicamentos , Humanos , Masculino , Dados de Sequência Molecular , Peptídeos/química , Reprodutibilidade dos Testes , Sensibilidade e EspecificidadeRESUMO
BACKGROUND: Chronic adipose tissue inflammation is a hallmark of obesity, triggering the development of associated pathologies, particularly type 2 diabetes. Long-chain n-3 PUFAs reduce cardiovascular events and exert well-established antiinflammatory effects, but their effects on human adipose tissue inflammation are unknown. OBJECTIVE: We investigated whether n-3 PUFAs reduce adipose tissue inflammation in severely obese nondiabetic patients. DESIGN: We treated 55 severely obese nondiabetic patients, scheduled to undergo elective bariatric surgery, with 3.36 g long-chain n-3 PUFAs/d (EPA, DHA) or an equivalent amount of butterfat as control, for 8 wk, in a randomized open-label controlled clinical trial. The primary efficacy measure was inflammatory gene expression in visceral and subcutaneous adipose tissue samples (subcutaneous adipose tissue and visceral adipose tissue), collected during surgery after the intervention. Secondary efficacy variables were adipose tissue production of antiinflammatory n-3 PUFA-derived eicosanoids, plasma concentrations of inflammatory markers, metabolic control, and the effect of the Pro12Ala PPARG polymorphism on the treatment response. RESULTS: Treatment with n-3 PUFAs, which was well tolerated, decreased the gene expression of most analyzed inflammatory genes in subcutaneous adipose tissue (P < 0.05) and increased production of antiinflammatory eicosanoids in visceral adipose tissue and subcutaneous adipose tissue (P < 0.05). In comparison with control subjects who received butterfat, circulating interleukin-6 and triglyceride concentrations decreased significantly in the n-3 PUFA group (P = 0.04 and P = 0.03, respectively). The Pro12Ala polymorphism affected the serum cholesterol response to n-3 PUFA treatment. CONCLUSIONS: Treatment with long-chain n-3 PUFAs favorably modulated adipose tissue and systemic inflammation in severely obese nondiabetic patients and improved lipid metabolism. These effects may be beneficial in the long-term treatment of obesity. This trial was registered at clinicaltrials.gov as NCT00760760.
Assuntos
Tecido Adiposo/efeitos dos fármacos , Ácidos Graxos Ômega-3/administração & dosagem , Inflamação/tratamento farmacológico , Obesidade/tratamento farmacológico , Tecido Adiposo/fisiologia , Adulto , Idoso , DNA/química , DNA/genética , Ácidos Graxos/sangue , Feminino , Humanos , Imuno-Histoquímica , Inflamação/sangue , Inflamação/genética , Interleucina-6/sangue , Masculino , Pessoa de Meia-Idade , Obesidade/sangue , Obesidade/genética , PPAR gama/genética , Reação em Cadeia da Polimerase , Polimorfismo de Nucleotídeo Único , Triglicerídeos/sangue , Adulto JovemRESUMO
In order to assess potential risks of exposure to environmental chemicals, more information on concomitant exposure to different chemicals is needed. We present data on chemicals in human milk of a cohort study (2004, 2005, 2006) of 54 mother/child pairs, where for the first time, cosmetic UV filters, synthetic musks, parabens and phthalate metabolites were analyzed in the same sample along with persistent organochlor pollutants (POPs), i.e., organochlor pesticides and metabolites, polybrominated diphenylethers and polychlorinated biphenyls (PCBs). The two groups of chemicals exhibited different exposure patterns. Six out of seven PCB congeners and a majority of pesticides were present in all milk samples, with significant correlations between certain PCB congener and pesticide levels, whereas the cosmetic-derived compounds, UV filters, parabens and synthetic musks, exhibited a more variable exposure pattern with inter-individual differences. UV filters were present in 85.2% of milk samples, in the range of PCB levels. Comparison with a questionnaire revealed a significant correlation between use of products containing UV filters and their presence in milk for two frequently used and detected UV filters, 4-methylbenzylidene camphor and octocrylene, and for the whole group of UV filters. Concentrations of PCBs and organochlor pesticides were within ranges seen in Western and Southern European countries. For several POPs, mean and/or maximum daily intake calculated from individual concentrations was above recent US EPA reference dose values. Our data emphasize the need for analyses of complex mixtures to obtain more information on inter-individual and temporal variability of human exposure to different types of chemicals.
Assuntos
Cosméticos/metabolismo , Exposição Materna/estatística & dados numéricos , Leite Humano/metabolismo , Compostos Orgânicos/metabolismo , Feminino , Éteres Difenil Halogenados/metabolismo , Humanos , Hidrocarbonetos Clorados/metabolismo , Hidrocarbonetos Halogenados/metabolismo , Parabenos/metabolismo , Perfumes/metabolismo , Praguicidas/metabolismo , Ácidos Ftálicos/metabolismo , Bifenilos Policlorados/metabolismo , Protetores Solares/metabolismo , Raios UltravioletaRESUMO
OBJECTIVE: The fibrin-derived peptide Bbeta15-42 has been shown to reduce infarct size in rodent models of ischemia-reperfusion injury. To increase its potential for translation into the clinic, we studied the effects of Bbeta15-42 in pigs, whose coronary anatomy is similar to that of humans. In addition, we evaluated the pharmacokinetics and safety of Bbeta15-42 in several species, including humans. DESIGN: Animal study and phase I trial. SETTING: University hospital and contract research laboratories. SUBJECTS: Pigs/healthy volunteers. INTERVENTIONS: Male farm-bred Landrace pigs were subjected to 1 hr of left anterior descending coronary artery occlusion followed by 3 hrs of reperfusion. At the time of reperfusion, Bbeta15-42 (2.4 mg/kg, n = 6) or random peptide (control; 2.4 mg/kg, n = 6) was administered as an intravenous bolus. As a positive control, pigs were subjected to ischemic preconditioning (n = 6). Cardiac damage and hemodynamics were recorded. Biodistribution and pharmacokinetics of Bbeta15-42 were determined in rats and dogs. In a phase I trial involving 30 male healthy volunteers, pharmacokinetics and safety were tested in a randomized, double-blinded, placebo-controlled, parallel-group, single ascending dose study. MEASUREMENTS AND MAIN RESULTS: Bbeta15-42 and ischemic preconditioning significantly reduced myocardial infarct size and troponin I levels. Bbeta15-42 also reduces interleukin-6 levels, underlining its anti-inflammatory properties. Furthermore, in humans, the pharmacokinetics of the peptide Bbeta15-42 were comparable to those of animals, and no serious adverse effects were observed. CONCLUSIONS: Bbeta15-42 elicits cardioprotection in pigs and is clinically safe in phase I testing of humans. This study confirms the new concept of a pathogenic role of fibrin derivatives in myocardial reperfusion injury, which can be inhibited by peptide Bbeta15-42.
Assuntos
Cardiotônicos/uso terapêutico , Produtos de Degradação da Fibrina e do Fibrinogênio/uso terapêutico , Infarto do Miocárdio/tratamento farmacológico , Fragmentos de Peptídeos/uso terapêutico , Traumatismo por Reperfusão/prevenção & controle , Adolescente , Adulto , Análise de Variância , Animais , Cardiotônicos/efeitos adversos , Cardiotônicos/farmacocinética , Cães , Método Duplo-Cego , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Produtos de Degradação da Fibrina e do Fibrinogênio/efeitos adversos , Produtos de Degradação da Fibrina e do Fibrinogênio/farmacocinética , Meia-Vida , Humanos , Masculino , Pessoa de Meia-Idade , Infarto do Miocárdio/patologia , Fragmentos de Peptídeos/efeitos adversos , Fragmentos de Peptídeos/farmacocinética , Ratos , Suínos , Distribuição TecidualRESUMO
Polyunsaturated fatty acids (PUFAs) modulate immune responses leading to clinically significant beneficial effects in a variety of inflammatory disorders. PUFA effects on T cells have been extensively studied, but their influence on human dendritic cells (DCs), which are the most potent antigen-presenting cells and play a key role in initiating immune responses, has not been elucidated so far. Here we show that PUFAs of the n-3 and n-6 series (arachidonic and eicosapentaenoic acid) affect human monocyte-derived DC differentiation and inhibit their activation by LPS, resulting in altered DC surface molecule expression and diminished cytokine secretion. Furthermore, the potency to stimulate T cells was markedly inhibited in PUFA-treated DCs. The PUFA-mediated block in LPS-induced DC activation is reflected by diminished TNF-alpha, IL-12p40, CD40, and COX-2 mRNA levels. Strikingly, typical LPS-induced signaling events such as degradation of IkappaB and activation of NF-kappaB were not affected by PUFAs, even though DC membrane lipid composition was markedly altered. Arachidonic and eicosapentaenoic acid both altered DC prostaglandin production, but inhibitors of cyclooxygenases and lipoxygenases did not abolish PUFA effects, indicating that the observed PUFA actions on DCs were independent of autoregulation via eicosanoids. These data demonstrate a unique interference with DC activation and function that could significantly contribute to the well known anti-inflammatory effects of PUFAs.